Biomedical subjects
Publications and source records attributed to P Arend.
A case of traumatic false aneurysm located in an unusual portion of the ulnar artery is presented and the clinical findings, diagnosis and treatments are considered. The authors report the first use of ultrasound-guided compression closure, as an alternative to surgical management of ulnar artery false aneurysms.
The authors report one case of solitary metastatic endometrial carcinoma of the spleen. Carcinomatous metastatic involvement of the spleen usually indicates widespread malignant disease. Solitary metastatic lesions in this organ are exceedingly rare and the literature reveals up today only three cases having a endometrial origin. The authors take this opportunity to make a review of the literature.
Dermoïd cyst of the bladder is an exceptional pathology. One case of hairy bladder tumors is describe with short review of the literature.
The "natural" anti-A antibody of the mouse is an autoantibody due to the age-dependent appearance of an A-like auto-reactive determinant, which is predominantly displayed by ovarian tissue and probably occurs in other tissues below the level of detection. The present study shows that this determinant is distinct from murine structures which react with xenogeneic anti-A antibody, and that it does not involve the widespread heterogenetic (Forssman-type) A-related specificity. Whereas xeno-reactive A-like structures, which combine with the human "natural" anti-A antibody, are exhibited by several murine tissues and Forssman-type structures by all of them, the murine "natural" anti-A antibody solely reflects the autoantigenic power of the particular determinant discovered in ovarian tissue. This determinant, which undergoes a unique genetic regulation, is present in both the ovary of the C57BL/10 inbred mouse and that of the NMRI outbred mouse and may thus represent a common murine component.
Explore the source record for details and available documents.
C57BL/10 inbred mice produce a "natural" antibody which in the presence of complement selectively lyses human blood group A erythrocytes, and the sera of females display significantly higher levels than the sera of males. This pronounced anti-A hemolysin production in females follows the appearance of specific endogenous A-determinants which are associated with water-soluble ovarian glycolipids specifically blocking the syngeneic anti-A hemolysin activity. Moreover, this hemolysin activity develops poorly in mice ovariectomized at the age of 20 days. The coincidental production of (auto)antigenic structures in morphologically and functionally normal ovarian tissue and of antibodies against them is thought to be tolerated through the modulation of a thymusdirected control mechanism.
Haemagglutinins which specifically combine with membrane determinants of human blood group A erythrocytes and which are distinguishable from any other haemagglutinin specificities display marked sex dependency in C57BL/10 mice. All the sera of 80-day-old C57BL/10 females exert moderate to strong anti-A haemagglutinin activities which could be detected only in approximately half of the sera of the males of the same age. Investigations of the murine tissues revealed that the production of anti-A haemagglutinins in females is reflected by simultaneous synthesis of strong endogenous receptors detected in the ovaries and associated with water-soluble glycolipid fractions. The receptor activity was demonstrated by means of haemagglutination inhibition in comparison with appropriate controls and glycolipid preparations from seventeen other different male and female tissues, and the inhibitory effects exerted by the ovarian glycolipids were statistically significant on the basis of multiple comparisons at the 1% level in each possible pair of effects.
The penicillins ciclacillin and dicloxacillin demonstrate marked similarities in biological activity but, as far as can be determined, differ substantially in respect to the degree of protein binding, which is relatively low for ciclacillin and relatively high for dicloxacillin. In mice infected with Staphylococcus aureus Smith, ciclacillin is considerably more active than dicloxacillin, although both drugs are similarly effective in vitro and similarly absorbed and eliminated in vivo. The high degree of protein binding exhibited by dicloxacillin could therefore very probably explain its relatively low chemotherapeutic activity. Moreover, the in vitro and in vivo findings of the study are inconsistent with the tenets of the tau/2 thesis.
In an attempt to explain the discrepancy between the weak in vitro activity and good clinical efficacy of ciclacillin, a time-dosage-efficacy study was made in order to investigate the relationship of the effectiveness of this antibiotic to the interval between experimental infection and administration in comparison to ampicillin, which because of its similar antimicrobial spectrum and completely different pharmacokinetic properties was particularly suitable for use in the study. Various single oral doses of both antibiotics were administered once to NMRI (SPF) mice at various intervals (0, 1, 2 or 3 h) following experimental infection with E. coli WT 102, E. coli 3033 or E. coli 026:B6 and the CD50's determined and compared statistically. It was demonstrated that the chemotherapeutic effectiveness of both antibiotics was markedly dependent on the interval between experimental infection and administration. Whereas ampicillin was superior to ciclacillin when drug and infective organism were administered simultaneously (0 h), ciclacillin was superior to ampicillin when it was administered 3 h after experimental infection. Both antibiotics were about equally effective when administered 1 or 2 h after infection. The difference in the serum concentrations and rates of absorption and excretion of the two drugs is assumed to be the reason for this phenomenon, and the pharmacokinetic characteristics of ciclacillin, in particular its rapid and almost complete absorption and rapid attainment of high peak serum levels, are discussed as at least a partial explanation of the difference in its in vitro and in vivo activities.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.